• Thrombo inCode is a dominant option in assessing the risk of VTE compared to the standard method currently used. • Based on a price of €180 for Thrombo inCode, this would be the dominant option (more effective and with lower costs than the standard method) in both populations (Table 1) • To conduct an economic analysis of the risk assessment of venous thromboembolism (VTE) from the perspective of the Spanish National Health System with Thrombo inCode versus conventional/standard method used to date (Factor V Leiden and Prothrombin G20210A).
[+]: Indicates that the standard method sub-tree has the same structure as the TiC sub-tree but it has been hidden to simplify the figure. 
